MENU
+Compare
PPH
ETF ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$99.44
Change
+$0.11 (+0.11%)
Net Assets
1.12B

PPH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index... Show more

Category: #Health
PPH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for PPH with price predictions
Nov 12, 2025

Momentum Indicator for PPH turns positive, indicating new upward trend

PPH saw its Momentum Indicator move above the 0 level on October 30, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on November 06, 2025. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PPH broke above its upper Bollinger Band on November 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), McKesson Corp (NYSE:MCK), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 150.84B. The market cap for tickers in the group ranges from 1.95B to 910.93B. LLY holds the highest valuation in this group at 910.93B. The lowest valued company is PRGO at 1.95B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was 14%. For the same ETF, the average monthly price growth was 27%, and the average quarterly price growth was 70%. OGN experienced the highest price growth at 21%, while PRGO experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was 70% and the average quarterly volume growth was 44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 36
P/E Growth Rating: 55
Price Growth Rating: 45
SMR Rating: 57
Profit Risk Rating: 62
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
PPH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com